1-Oxa-6-azaspiro[3.4]octane hemioxalate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Oxa-6-azaspiro[3.4]octane hemioxalate
• 英文别名: 1-oxa-7-azaspiro[3.4]octane;oxalic acid
• 化学式: C14H24N2O6
• 分子量: 316.35
• InChiKey: ZUGYAGVFZOLOND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.57
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10975081B2

  公开（公告）日：2021-04-13

  Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

  本发明公开了可抑制 LRRK2 激酶活性的取代融合吡唑（例如取代吲唑）、含有它们的药物组合物以及它们在帕金森病治疗中的用途。
• HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3325449B1

  公开（公告）日：2021-01-13
• COMPOUNDS
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20200079777A1

  公开（公告）日：2020-03-12

  Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).